A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants With Type 1 Diabetes Mellitus
Latest Information Update: 01 Aug 2025
At a glance
- Drugs CT 868 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Sponsors Carmot Therapeutics; Roche
Most Recent Events
- 17 Jul 2025 Status changed from active, no longer recruiting to completed.
- 28 Mar 2025 Planned End Date changed from 31 Oct 2024 to 8 Jul 2025.
- 28 Mar 2025 Planned primary completion date changed from 31 Oct 2024 to 8 Jul 2025.